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Background: The purpose of this study was to determine the prevalence and risk   factors 
for   cervical squamous intraepithelial lesions (SIL) among women infected with human 
  immunodeficiency virus type 1 (HIV-1) receiving care at the Federal Medical Center Makurdi, 
Nigeria.
Methods: Between March and December 2009, a total of 253 women infected with HIV-1 
had cervical smears taken for cytology. HIV-1 RNA viral load and CD4 counts were also 
measured.
Results: Of the 253 women, cervical SIL were present in 45 (17.8%). However, abnormal 
cervical cytology was noted in 146 (57.7%). Of those with abnormal cervical cytology, 
101 (39.9%) women had atypical squamous cells of undetermined significance, 16 (6.3%) 
had   low-grade SIL, and 29 (11.5%) women had high-grade SIL. The median CD4 lympho-
cyte count was lower in participants with cervical SIL compared with those without (132 
versus 184 cells/mm3; P = 0.03). The median HIV-1 RNA viral load was higher in women 
with cervical SIL (102,705 versus 64,391 copies/mL; P = 0.02). A CD4 lymphocyte count 
of 200 cells/mm3 and an HIV-1 RNA viral load of 10,000 copies/mL were found to be 
significantly associated with cervical SIL.
Conclusion: A high prevalence of cervical SIL was found among HIV-1-infected women in 
Makurdi, Nigeria. Increased immune suppression and HIV-1 viremia are significantly   associated 
with cervical SIL.
Keywords: cervical squamous intraepithelial lesions, human immunodeficiency virus, risk 
factors, immunosuppression, cervical dysplasia, Nigeria
Introduction
Cancer of the uterine cervix is the second most common cancer among women 
  worldwide, with an estimated 493,000 new cases in 20021,2 and over 250,000 deaths 
in 2005.3 Without urgent action, deaths from cervical cancer are projected to rise by 
almost 25% over the next ten years.3 Therefore, cervical cancer presents a serious 
global problem.2 Over 80% of cases of cervical cancer occur in developing countries 
where it represents the commonest malignancy affecting women.4,5 In Nigeria, it is 
the commonest cancer of the female genital tract.6 Most women who die from   cervical 
cancer, particularly in developing countries, are in the prime of their life. They may be 
raising children, caring for their family, and contributing to the social and economic 
life of their town or village. Their death is both a personal tragedy and a sad and 
unnecessary loss to their family and their community.3
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Invasive cancer of the cervix is considered to be a 
preventable condition, given that it is associated with a 
long preinvasive stage, making it amenable to screening 
and treatment as long as it is detected early and managed 
effectively.3,7 Cancer of the cervix has been classified as an 
acquired immune deficiency syndrome (AIDS) defining can-
cer by the US Centers for Disease Control and   Prevention.8 
Unfortunately, the global human immunodeficiency virus 
(HIV) epidemic continues to expand, with about five mil-
lion people becoming infected each year and an estimated 
39.5 million people living with HIV at the end of 2006.9,10 
With an estimated 2.95 million people living with HIV in 
Nigeria in 2008, Nigeria ranks as one of the countries with 
the highest burden of HIV infection in the world, next only 
to India and South Africa.11 Over the decades, the epidemic, 
once dominated by infected males, has become progressively 
feminized. In sub-Saharan Africa, where about two-thirds 
of the global disease burden occurs, 57% of adults living 
with HIV are women.12 As more women contract the virus, 
the risk of cervical squamous intraepithelial lesions (SIL) 
or cervical intraepithelial neoplasia and ultimately cervical 
cancer increases.13
Despite the fact that HIV infection and cervical 
  cancer constitute a major reproductive health challenge in 
  Nigeria and Africa, only a few studies have investigated 
the   relationship between HIV infection and cervical SIL. 
Both CD4 lymphocyte count and HIV RNA viral load are 
independent predictors of the course of HIV/AIDS, and 
the frequency of occurrence and severity of cervical SIL in 
HIV-infected women increase as the CD4 count declines.14 
However, the role of HIV RNA viral load and   antiretroviral 
therapy regarding the risk of cervical SIL has not been 
satisfactorily established. This study aimed to determine 
the prevalence of cervical SIL among a cohort of women 
infected with HIV-1 and to identify its relationship with risk 
factors, CD4 cell count, and HIV-1 RNA levels in Makurdi, 
north central Nigeria.
Materials and methods
The Federal Medical Center Makurdi, is situated in Benue 
State, a low resource setting with the highest burden of HIV 
infection (seroprevalence 10.6%) in the Nigerian federation.11 
The HIV care clinic of the center, located on the banks of the 
River Benue, is a regional reference center for comprehen-
sive treatment and support of people living with HIV . This 
study was approved by the research ethics committee of the 
Federal Medical Center Makurdi in October 2008. After 
detailed explanation of the study and clinical procedures, 
all 253 participants provided their written consent in English 
and pretested translations of the local languages for illiterate 
women. Consecutive nonpregnant clients were recruited into 
the study between March and December 2009. Other eligibil-
ity criteria included documented evidence of HIV-1 infection 
by Western blot (Immunetics Inc, Boston, MA) and current 
absence of acute illness. Excluded from the study were clients 
who declined to participate, pregnant women (from menstrual 
history), women in the puerperium, women with obvious 
genital tract lesions and infection (referred for appropriate 
treatment), and those with a prior history of treatment for 
preinvasive and invasive cervical neoplasia.
Demographic data were collected using a pro forma, 
and included age, parity, marital status, number of lifetime 
sexual partners, history of tobacco smoking, and previous 
sexually transmitted infection. History of use of highly active 
antiretroviral therapy (HAART) was obtained and verified 
from client records. All study participants on HAART dur-
ing the study period were on a regimen consisting of two 
nucleoside reverse transcriptase inhibitors (stavudine or 
zidovudine and lamivudine) and one non-nucleoside reverse 
transcriptase inhibitor (nevirapine or efavirenz). All patients 
on HAART were receiving first-line drugs according to 
national guidelines. None of the clients recruited were on 
second-line drugs.
The CD4 count was measured using flow cytometry 
(Cyflow; Partec, Germany) and reported as cells per cubic 
milliliter of blood (cells/mm3). HIV-1 RNA viral load was 
determined by nucleic acid amplification (Roche-Ampliclor 
HIV-1 monitor test, version 1.5; Roche Molecular Systems 
Inc, Branchburg, NJ). Results were expressed as the number 
of RNA copies per milliliter of plasma (copies/mL). Values 
of 400 copies/mL and below were regarded as undetectable. 
Blood samples for CD4 count and viral load were taken on 
the same day as the Papanicolaou smear.
All pelvic examinations were performed by a gynecolo-
gist or a trained gynecology resident. The clients were placed 
in the lithotomy position and a Cusco’s speculum applied. 
Following visual inspection with a good light source, the 
cervix was assessed for gross lesions and abnormal discharge. 
Cervical smears were obtained using the Ayre’s spatula from 
both the ectocervix and endocervix. Smears were made at 
two points on prelabelled glass slides and then fixed imme-
diately in 95% (v/v) alcohol in coupling jars. These were 
delivered to the cytopathology laboratory for staining and 
microscopic examination. All the slides were stained using 
the Papanicolaou staining technique. The fixed slides were 
stained in Harris hematoxylin. The smear was decolorized 
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with acid alcohol and rinsed in Scott’s tap water. They were 
then stained in orange G stock solution and finally stained 
with Eosin Azure 50. The slides were further rinsed in two 
changes of 95% alcohol, cleared in xylene, and mounted in a 
neutral synthetic resin medium. To ensure unbiased reporting, 
the cytopathologist was blinded to the clinical profile of the 
samples. Cytology was reported using the Bethesda system 
of classification by an experienced cytologist/pathologist. 
The smears were reported as normal, inflammatory, atypi-
cal squamous cells of undetermined significance, low-grade 
SIL, or high-grade SIL. Women with initial “inflammatory” 
Papanicolaou smear results were treated appropriately and 
reconsidered afresh for recruitment into the study. With the 
exception of patients with a normal report, all others were 
referred to the gynecology clinic for further evaluation.
Statistical analysis
All data were entered and the analysis was performed using 
the Epi-info version 3.3.2 (CDC Atlanta, GA) computer soft-
ware program. The t-test was used to compare differences in 
normally distributed continuous variables between subjects 
with and without cervical SIL. Non-normally distributed vari-
ables were compared using the Mann-Whitney test. Univariate 
analysis using the Chi-square (χ2)   statistic was performed to 
identify risk factors associated with cervical SIL. Multivariate 
logistic regression was used to identify independent risk fac-
tors for cervical SIL. Variables were entered into the model if 
their P value on univariate analysis was 0.25 or less. P  0.05 
was considered to be statistically significant.
Results
The mean age of the 253 participants was 34.2 ± 6.4 (range 
20–60) years. The median number of lifetime sexual partners 
was five (range 0–60), and 107 (42.3%) women had a prior 
history of sexually transmitted infection (Table 1). A total of 
104 (41.1%) participants in the study were on HAART, with 
a mean duration of use of 16 ± 2 (range 1–36) months. The 
predominant HAART regimen was lamivudine, stavudine, 
and nevirapine (67.3%), while zidovudine, lamivudine, and 
nevirapine was the regimen used by 26% of the patients. 
Other regimens were being taken by 6.7% of the patients. The 
median CD4 count was 174 (range 12–1468) cell/mm3. HIV-1 
RNA levels were detectable in 205 (81.0%) women, with a 
median detectable level of 64,786 (range 426–1,854,296) 
copies/mL. There were 146 (57.7%) women with abnormal 
cervical cytology. Of these, 101 (39.9%) women had atypi-
cal squamous cells of undetermined significance. SIL was 
present in 45 (17.8%) women. Among the women with SIL, 
low-grade SIL and high-grade SIL was present in 16 (6.3%) 
and 29 (11.5%) of cases, respectively. No case of invasive 
cervical cancer was identified.
The mean age of participants with SIL was 36 ± 7 
years compared with 33 ± 5 years for women without SIL 
(P = 0.009; Table 2). However, the parity of participants was 
similar in the two groups. Women with SIL did not have a 
greater number of lifetime sexual partners and had rates of 
history of sexually transmitted infections similar to that of the 
women without SIL. Likewise, tobacco smoking and mean 
duration on HAART were similar in women with and without 
SIL (Table 2). Women with SIL had a median CD4 cell count 
of 132 cells/mm3 compared with 184 cells/mm3 for those 
without SIL (P = 0.03). The HIV-1 RNA viral load was also 
significantly higher in women with SIL compared with that 
in women without SIL (102,705 versus 64,391 copies/mL, 
respectively; P = 0.002, Table 2).
The results of the multivariate analyses are presented 
in Table 3. Having adjusted for other determinants, the risk 
Table 1 Key sociodemographic characteristics and risk factors 
for squamous intraepithelial lesions in 253 women in Makurdi, 
Nigeria, infected with HIV-1a
Characteristic Value
Age (years) 34.2 (±6.4)
Parity 2 (±2)
Educational status
  None 69 (27.3)
  Primary 19 (7.5)
  Secondary 107 (42.3)
  Tertiary 58 (22.9)
Married 134 (53.0)
Previous sexually transmitted infection 107 (42.3)
Tobacco smoking 28 (11.0)
Number of lifetime sexual partners 5 (±4)
Use of HAArT 104 (41.1)
CD4 count, cells/mm3
 # 200 125 (49.4)*
  201–499 105 (41.5)
 $ 500 23 (9.1)
HIV-1 rNA, copies/mL
 $ 400 205 (81.0)
 # 400 48 (19.0)
Cervical cytology
  Normal 107 (42.2)
  ASCUS 101 (39.9)
  LSIL 16 (6.3)
  HSIL 29 (11.5)
Notes: aValues are given as mean ± standard deviation or number (percentage);   
*21 naive women were having CD4 estimation for the first time.
Abbreviations:  ASCUS,  atypical  squamous  cells  of  undetermined  significance; 
HAArT, highly active antiretroviral therapy; LSIL, low-grade squamous intraepithelial 
lesions;  HSIL,  high-grade  squamous  intraepithelial  lesions;  HIV-1,  human 
immunodeficiency virus type 1.
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of all types of SIL was significantly associated with a CD4 
count  200 cells/mm3 and HIV-1 RNA viral load .10,000 
copies/mL. Low CD4 count 200 cells/mm3 and HIV-1 
RNA viral load .10,000 copies/mL remained significantly 
associated with SIL when the variables were analyzed for 
risk of either low-grade SIL alone or high-grade SIL alone.
Discussion
During the early days of the HIV epidemic, HIV-infected 
women who had cervical human papillomavirus infection 
and SIL frequently died of AIDS well before developing 
invasive cervical cancer. However, following the introduc-
tion of HAART, the clinical course of HIV has been substan-
tially prolonged, making HIV-infected women a clinically 
significant group of patients who have an increased risk of 
acquiring human papillomavirus infection and developing 
SIL and invasive cervical cancer.15 This study provides the 
first comprehensive analysis of the prevalence of cervical 
SIL, the precursor to invasive cervical cancer, in this popula-
tion in Makurdi, Nigeria.
The prevalence of SIL among the HIV-1 infected women 
in this study was 17.8%. Anorlu et al6 recently reported a 
lower prevalence of 10.9% in HIV-positive women in Lagos, 
Nigeria. The reported prevalence in this study is also higher 
than the 2.9% and 13.3%, respectively, reported by Kapiga 
et al16 among HIV-seropositive pregnant women in Tanzania 
and Chalermchockcharoenkit et al17 among HIV-infected 
women by postpartum Papanicolaou smear in Thailand. 
The fact that the other studies were conducted among 
pregnant and postpartum women may have contributed to 
the observed variation. However, other researchers have 
reported higher prevalences in Africa involving HIV-positive 
women in Jos, Nigeria (29%),14 commercial sex workers 
in Kenya (26%),18 and sexually transmitted disease clinic 
attendees in Zambia (56%).19 The difference between the 
findings of this study and those of other researchers may be 
attributed to the different populations sampled and possibly 
the different stages of HIV infection. Elsewhere, Lehtovirta 
et al20 found a prevalence of 33% in a cohort of HIV-infected 
women in Helsinki, Finland. The prevalence of SIL in the 
general Nigerian population ranges from 4.1% to 11.8%.14 
These rates in the general population are less than the 17.8% 
reported in this study.
Previous studies have not satisfactorily established 
a protective effect of antiretroviral treatment on the risk 
of SIL. HAART showed some potential effect in the 
Women’s Interagency HIV study.21 Heard et al22 showed 
that HAART had a positive impact on regression of SIL, 
and this was associated with increasing CD4 cell counts. 
In other studies, the effect of HAART on the prevalence 
of SIL has not been significant14,20 or the prevalence of SIL 
has remained unchanged.23 Similarly in this study, the use 
of HAART was not associated with a significant reduction 
in the risk of SIL.
Immunosuppression by HIV infection is a strong risk 
factor for SIL. In this study, 49.4% of HIV-positive women 
had CD4 counts 200 cells/mm3, which is diagnostic of 
immunologic AIDS. In a recent review in Jos, Nigeria, Agaba 
et al14 found that 60.9% of their 369 HIV-positive women had 
CD4 counts 200 cells/mm3. The lower percentage of women   
Table 2 Demographic characteristics and selected risk factors for 
HIV-1 infected women with and without squamous intraepithelial 
lesions in Makurdi, Nigeriaa (n = 253)
Characteristic SIL (n = 45)b No SIL (n = 208)c P value
Age, years 36 ± 7 33 ± 5 0.009
Parity 2 ± 7 2 ± 3 0.34
Lifetime sexual partners 5 ± 4 5 ± 3 0.84
Mean duration  
on HAArT (months)
17 ± 6 15 ± 6 0.32
Tobacco smoking, % 9.3 7.1 0.47
Previous sexually  
transmitted infection, %
41.7 36.5 0.43
Median CD4 count,  
cell/mm3
132 184 0.03
Median HIV-1 rNA,  
copies/mL
102,705 64,391 0.002
Notes: aValues are given as the mean ± standard deviation, percentage, or median, 
unless otherwise indicated; bSIL group consists of those with low-grade squamous 
intraepithelial  lesions  (n  =  16)  and  high-grade  squamous  intraepithelial  lesions 
(n = 29); cno SIL group consists of those with normal smears (n = 107) and those 
with atypical squamous cells of undetermined significance (n = 101).
Abbreviations:  HAArT,  highly  active  antiretroviral  therapy;  SIL,  squamous 
intraepithelial lesions; HIV-1, human immunodeficiency virus type 1.
Table 3 Multivariate analysis of risk factors for cervical SIL among HIV-1 infected women in Makurdi, Nigeria
Variable all SIL Low-grade SIL High-grade SIL
AOR 95% CI P value AOR 95% CI P value AOR 95% CI P value
Age . 35 years 1.29 0.68–2.34 0.35 1.29 0.68–2.34 0.35 1.02 0.63–2.17 0.79
CD4 count  200 cells/mm3 3.64 1.40–5.17 0.04 3.63 1.39–5.16 0.05 4.95 2.16–7.83 0.002
HIV-1 rNA . 10000 copies/mL 2.58 1.08–3.87 0.03 2.58 1.08–3.87 0.03 3.67 1.73–6.39 0.001
Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; HIV-1, human immunodeficiency virus type 1; SIL, squamous intraepithelial lesions.
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with immunologic AIDS in this study may partly explain the 
lower prevalence of SIL of 17.8% in this study as compared 
with 29% in the Jos study. This study also showed that the 
CD4 count was inversely associated with SIL, and women 
with a CD4 count 200 cells/mm3 were at greater risk of SIL 
compared with women with CD4 counts .200 cells/mm3. 
This finding is in accordance with several other studies 
involving HIV-positive women.8,14,16,17,20,24 Davis et al13 
reported that the strongest predictor of genital dysplasia was 
a nadir CD4 and CD4 count 200 cells/mm3. Prolonged 
CD4 lymphopenia in patients infected with HIV results in 
defective T-cell proliferation regardless of the current CD4 
count or viral load.14 The CD4 count was independent of 
HAART use and HIV-1 RNA viral load as a risk factor for 
SIL in this study.
HIV-1 RNA levels have been directly correlated with a 
higher risk of SIL.25 In this study, the median HIV-1 RNA 
viral load was significantly higher in patients with SIL than 
in those without SIL. Furthermore, an HIV-1 RNA viral 
load .10,000 copies/mL was associated with SIL in mul-
tivariate analysis. However, a high level of HIV/RNA does 
not always predict the risk of SIL, because some studies 
have failed to show a positive association.13 For instance, 
Agaba et al14 observed that although the HIV viral load was 
higher in patients with SIL, it was not predictive of SIL in 
multivariate analysis.
This study is not without important limitations. First, it 
was essentially a cross-sectional study, with a Papanicolaou 
smear taken only once at recruitment. Follow-up with mul-
tiple Papanicolaou smears over a period of time would have 
been ideal. Another limitation was the fact that SIL was deter-
mined using only cytology without histologic confirmation. 
There was also no end-of-study colposcopy to seek occult 
lesions. This leaves the possibility of underestimation of the 
endpoints of low-grade SIL and high-grade SIL.
In conclusion, a high prevalence of cervical SIL was 
found among HIV-1 infected women in Makurdi, Nigeria. 
Decreased CD4 cell counts and increasing HIV-1 RNA 
viral load were associated with cervical SIL. CD4 cell 
counts 200 cells/mm3 and HIV-1 RNA viral loads .10,000 
copies/mL were significantly associated with cervical SIL. 
Accordingly, HIV treatment programs and clinics must as a 
matter of policy institute comprehensive reproductive health 
care services for this high-risk group, including routine 
Papanicolaou smear screening.
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